231 related articles for article (PubMed ID: 9678133)
1. Oral contraceptives and venous thromboembolism: an epidemiological review.
Lidegaard O
Eur J Contracept Reprod Health Care; 1996; 1(1):13-20. PubMed ID: 9678133
[TBL] [Abstract][Full Text] [Related]
2. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
Lidegaard O
Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
[TBL] [Abstract][Full Text] [Related]
3. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
[TBL] [Abstract][Full Text] [Related]
4. Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies.
Rekers H; Norpoth T; Michaels MA
Eur J Contracept Reprod Health Care; 1996; 1(1):21-30. PubMed ID: 9678134
[TBL] [Abstract][Full Text] [Related]
5. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
Meurer LN; Slawson JG
J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
[No Abstract] [Full Text] [Related]
6. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
7. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
[TBL] [Abstract][Full Text] [Related]
8. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
[TBL] [Abstract][Full Text] [Related]
9. Modern oral contraceptives and cardiovascular disease.
Rosenberg L; Palmer JR; Sands MI; Grimes D; Bergman U; Daling J; Mills A
Am J Obstet Gynecol; 1997 Sep; 177(3):707-15. PubMed ID: 9322646
[TBL] [Abstract][Full Text] [Related]
10. Increased risk from third-generation progestogens: fuzzy logic or fuzzy science?
Corson SL
J Reprod Med; 1996 Sep; 41(9):711-2. PubMed ID: 8887199
[TBL] [Abstract][Full Text] [Related]
11. The new pills: awaiting the next generation of oral contraceptives.
Klitsch M
Fam Plann Perspect; 1992; 24(5):226-8. PubMed ID: 1426186
[TBL] [Abstract][Full Text] [Related]
12. Newer oral contraceptives and the risk of venous thromboembolism.
Walker AM
Contraception; 1998 Mar; 57(3):169-81. PubMed ID: 9617533
[TBL] [Abstract][Full Text] [Related]
13. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.
Lewis MA; Heinemann LA; MacRae KD; Bruppacher R; Spitzer WO
Contraception; 1996 Jul; 54(1):5-13. PubMed ID: 8804801
[TBL] [Abstract][Full Text] [Related]
14. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
Heinemann LA; Dinger JC; Assmann A; Minh TD
Contraception; 2010 May; 81(5):401-7. PubMed ID: 20399946
[TBL] [Abstract][Full Text] [Related]
15. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
Winkler UH
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
[TBL] [Abstract][Full Text] [Related]
16. The use of a large-scale surveillance system in Planned Parenthood Federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives.
Burnhill MS
Int J Fertil Womens Med; 1999; 44(1):19-30. PubMed ID: 10206196
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptives and venous thromboembolism.
Paul C
N Z Med J; 1996 Nov; 109(1033):413-5. PubMed ID: 8941290
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptives and venous thromboembolism: consensus conference statement.
Dialogues in Contraception Consensus Conference (1995: Chicago)
Dialogues Contracept; 1996; ():1-8. PubMed ID: 12320455
[TBL] [Abstract][Full Text] [Related]
19. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives.
Schwingl PJ; Shelton J
Contraception; 1997 Mar; 55(3):125-9. PubMed ID: 9114999
[TBL] [Abstract][Full Text] [Related]
20. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
Spitzer WO; Lewis MA; Heinemann LA; Thorogood M; MacRae KD
BMJ; 1996 Jan; 312(7023):83-8. PubMed ID: 8555935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]